A Medical Device Daily
Grant Life Sciences (Los Angeles) reported it has received notice from the U.S. Patent and Trademark Office that Patent No. 7,267,961 - "peptides from the E7 protein of human papilloma viruses 16 and 18 for detecting and or diagnosing cervical and other Human papilloma virus associated cancers"- will issue today.
"Of course we are extremely pleased by the issuance of this patent, which is an important part of a comprehensive IP portfolio focusing on HPV detection and diagnostic technologies, including domestic patents, international patents and patent applications, that Grant Life Sciences is overseeing," said Hun-Chi Lin, PhD, Grant's president and chief scientist.
"No doubt, this is a very significant development for Grant Life Sciences," Lin said. "This patent would protect our investment to date in the development of our serum-based test for cervical cancer and allows us to move forward confidently in seeking an appropriate development-and-commercialization partner."
Grant Life Sciences is a development-stage company, and engages in the research and development of diagnostic kits for the screening, monitoring, and diagnosis of diseases with emphasis on women's health, infectious diseases, and cancers.